Ying Cheng

机构：Naval University of Engineering, Jilin Province Tumor Hospital, Jiangsu Provincial Center for Disease Control and Prevention, Nanjing Medical University · ORCID：0000-0001-9908-597X

发表论文 1002 篇 · 总被引 45302 次 · h-index 86

代表论文

• Novel CDK2/4/6 inhibitor culmerciclib (TQB3616) plus fulvestrant in previously treated, HR-positive, HER2-negative advanced breast cancer: a randomized, double-blind, phase 3 trial (2025 · Signal Transduction and Targeted Therapy · 被引 2)
• Evolocumab protects mice from radiation-induced damage by affecting hematopoietic cell lineage (2026 · Genomics)
• Pembrolizumab Plus Chemotherapy for Metastatic Squamous Non‒Small-Cell Lung Cancer: Long-Term Follow-Up of the KEYNOTE-407 China Study (2026 · JTO Clinical and Research Reports)
• Glutamine Starvation Induces Ferroptosis in NSCLC via AMPK/PDZD8-Mediated Ferritinophagy (2026 · Nutrients)
• Supplementary Figure S1 from Anlotinib in Locally Advanced or Metastatic Radioiodine-Refractory Differentiated Thyroid Carcinoma: A Randomized, Double-Blind, Multicenter Phase II Trial (2025)
• Supplementary Table S2 from Early Clearance of Plasma <i>Epidermal Growth Factor Receptor</i> Mutations as a Predictor of Outcome on Osimertinib in Advanced Non–Small Cell Lung Cancer; Exploratory Analysis from AURA3 and FLAURA (2025)